RAX2

Across TCGA pan-cancer cohorts, RAX2 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RAX2’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where RAX2 RNA is repressed in tumor relative to normal tissue. In most cancer types RAX2 is over-expressed in tumor, although a few such as UCEC and BRCA show the opposite, repressed pattern.

UCEC, BRCA, and BLCA are the cancer types where RAX2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAX2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	III,IV	−1.127	<.001	6	view →
BRCA	Female	II,III,IV	−0.093	<.001	6	view →
BLCA	All	III,IV	+0.020	.009	3	view →
PRAD	All	All	−0.035	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RAX2–UCEC

Open the UCEC breakdown →